# Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing Chorea

> **NCT01019473** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 44 (actual)

## Conditions studied

- Huntington's Disease
- Chorea

## Interventions

- **DRUG:** AFQ056
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01019473
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-11
- **Primary completion:** 2011-08
- **Final completion:** —
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2011-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01019473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01019473, "Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing Chorea". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01019473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*